Asset Details
Do you wish to reserve the book?
Drug company Aspen may pay NHS £8m after investigation alleges illegal deal to hike drug price
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Drug company Aspen may pay NHS £8m after investigation alleges illegal deal to hike drug price
Do you wish to request the book?
Drug company Aspen may pay NHS £8m after investigation alleges illegal deal to hike drug price
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Drug company Aspen may pay NHS £8m after investigation alleges illegal deal to hike drug price
2019
Overview
The drug company Aspen may have to pay the NHS £8m (€8.7m; $9.7m) after an investigation by the Competition and Markets Authority (CMA) into an arrangement it made with two rival companies, which left it as the sole supplier of a drug and therefore able to set prices without competition.1 The CMA suspected that the 2016 arrangement had broken competition law, as Aspen was believed to have paid competitors to stay out of the market. [...]of the ongoing investigation Aspen approached the CMA and offered to resolve the issue by putting certain actions in place, including a payment of £8m to be divided among England, Scotland, Wales, and Northern Ireland. The CMA said that the offer includes Aspen admitting that “it was party to an illegal, anti-competitive agreement, by way of settlement”; committing to paying the compensation without the government needing to launch court proceedings; committing to ensuring fair competition with a least two suppliers of fludrocortisone in the UK; and agreeing to pay a maximum fine of £2.1m once the investigation has concluded.
Publisher
BMJ Publishing Group LTD
Subject
